With the demand for the COVID-19 vaccine vastly exceeding the supply, the distribution of the vaccine has proven to be bumpy across the U.S. Kaiser helps us understand why.
The CDC and FDA approved Pfizer/BioNTech and Moderna for emergency use for the United States last December, with the first doses given to frontline health care workers in acute care settings (hospitals and health care facilities). But in February we still find ourselves in a difficult situation – though the roll-out has picked up, distribution remains slow, and the vaccine supply is still limited. Many states still have unaccounted doses, which was complicated by the former Presidential administration refusing to facilitate a smooth handoff to the incoming administration. But happily, distribution is picking up, and more supply will be available in the United States soon. A little patience now will pay off in the near future.